V C Wing1, M Shoaib. 1. Psychobiology Research Laboratories, School of Neurology, Neurobiology and Psychiatry, University of Newcastle, Newcastle Upon Tyne, UK.
Abstract
RATIONALE: At present, there is a lack of an established animal model to demonstrate the clinical efficacy of smoking cessation agents in the laboratory. The aim of this study was to compare the effects of the antidepressants bupropion and nortriptyline, clinically proven smoking cessation aids, within a rodent model of a nicotine withdrawal based on somatic measures. MATERIALS AND METHODS: Male hooded Lister rats were chronically exposed to nicotine (3.16 mg kg1 day1) for 7 days via SC implanted ALZET osmotic minipumps. Animals were acutely pre-treated with bupropion (10, 30 or 60 mg/kg, IP) or nortriptyline (1.5, 4.7 and 15 mg/kg, IP), and nicotine withdrawal was precipitated by mecamylamine (1 mg/kg). RESULTS: Precipitation of nicotine withdrawal led to an increase in somatic signs including body shakes, chews, eye blinks, foot licks, head shakes and ptosis. Bupropion dose-dependently decreased the total abstinence scores and reduced the occurrence of some individual somatic signs. Pre-treatment with 60 mg/kg bupropion did not result in a significant increase in total abstinence scores or individual somatic signs scores after mecamylamine challenge, compared to the mecamylamine control group, suggesting nicotine withdrawal is fully attenuated at this dose. Similarly, the highest dose of nortriptyline reduced total abstinence scores and some individual somatic signs to the level of the mecamylamine control group. However, nortriptyline was only effective at alleviating somatic measures of withdrawal at doses which also suppressed locomotor activity. CONCLUSION: In concurrence with clinical findings proposing alleviation of withdrawal states as a possible mechanism of bupropion and nortriptyline's smoking cessation action, both drugs were found to ameliorate somatic signs of nicotine withdrawal in rodents.
RATIONALE: At present, there is a lack of an established animal model to demonstrate the clinical efficacy of smoking cessation agents in the laboratory. The aim of this study was to compare the effects of the antidepressants bupropion and nortriptyline, clinically proven smoking cessation aids, within a rodent model of a nicotine withdrawal based on somatic measures. MATERIALS AND METHODS: Male hooded Lister rats were chronically exposed to nicotine (3.16 mg kg1 day1) for 7 days via SC implanted ALZET osmotic minipumps. Animals were acutely pre-treated with bupropion (10, 30 or 60 mg/kg, IP) or nortriptyline (1.5, 4.7 and 15 mg/kg, IP), and nicotine withdrawal was precipitated by mecamylamine (1 mg/kg). RESULTS: Precipitation of nicotine withdrawal led to an increase in somatic signs including body shakes, chews, eye blinks, foot licks, head shakes and ptosis. Bupropion dose-dependently decreased the total abstinence scores and reduced the occurrence of some individual somatic signs. Pre-treatment with 60 mg/kg bupropion did not result in a significant increase in total abstinence scores or individual somatic signs scores after mecamylamine challenge, compared to the mecamylamine control group, suggesting nicotine withdrawal is fully attenuated at this dose. Similarly, the highest dose of nortriptyline reduced total abstinence scores and some individual somatic signs to the level of the mecamylamine control group. However, nortriptyline was only effective at alleviating somatic measures of withdrawal at doses which also suppressed locomotor activity. CONCLUSION: In concurrence with clinical findings proposing alleviation of withdrawal states as a possible mechanism of bupropion and nortriptyline's smoking cessation action, both drugs were found to ameliorate somatic signs of nicotine withdrawal in rodents.
Authors: J R Hughes; S B Gulliver; J W Fenwick; W A Valliere; K Cruser; S Pepper; P Shea; L J Solomon; B S Flynn Journal: Health Psychol Date: 1992 Impact factor: 4.267
Authors: B D Jamerson; M Nides; D E Jorenby; R Donahue; P Garrett; J A Johnston; M C Fiore; S I Rennard; S J Leischow Journal: Clin Ther Date: 2001-05 Impact factor: 3.393
Authors: D H Malin; J R Lake; P Newlin-Maultsby; L K Roberts; J G Lanier; V A Carter; J S Cunningham; O B Wilson Journal: Pharmacol Biochem Behav Date: 1992-11 Impact factor: 3.533
Authors: F Scott Hall; Andre Der-Avakian; Thomas J Gould; Athina Markou; Mohammed Shoaib; Jared W Young Journal: Neurosci Biobehav Rev Date: 2015-06-06 Impact factor: 8.989
Authors: Xuesi M Shao; Siyu Liu; Eon S Lee; David Fung; Hua Pei; Jing Liang; Ross Mudgway; Jingxi Zhang; Jack L Feldman; Yifang Zhu; Stan Louie; Xinmin S Xie Journal: J Appl Physiol (1985) Date: 2018-09-20
Authors: M Imad Damaj; Sheri D Grabus; Hernan A Navarro; Robert E Vann; Jonathan A Warner; Lindsey S King; Jenny L Wiley; Bruce E Blough; Ronald J Lukas; F Ivy Carroll Journal: J Pharmacol Exp Ther Date: 2010-06-24 Impact factor: 4.030
Authors: Adrie W Bruijnzeel; Mahendra Bishnoi; Irma A van Tuijl; Kim F M Keijzers; Kate R Yavarovich; Tim M Pasek; Jenna Ford; Jon C Alexander; Hidetaka Yamada Journal: Psychopharmacology (Berl) Date: 2010-08-10 Impact factor: 4.530
Authors: Natalie E Gentile; Julie D Andrekanic; Tracy E Karwoski; R Kenneth Czambel; Robert T Rubin; Michael E Rhodes Journal: Brain Res Bull Date: 2011-03-17 Impact factor: 4.077